Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

AMRO.  We initiated a study called FOCUS FH late last year designed to support the addition of severe heterozygous FH to the label for KYNAMRO."

"While KYNAMRO is our flagship drug, our pipeline goes well beyond KYNAMRO.  With drugs in numerous therapeutic areas, we have many opportunities for both short- and long-term revenue growth.  We have several drugs that may provide substantial commercial opportunities with product launches that could occur within the next five years.  These include our TTR amyloidosis and Spinal Muscular Atrophy drugs from our severe and rare disease franchise, which, due to the significant unmet medical need and orphan patient populations, could warrant an accelerated path to market.  We expect that, if successful, they could be available for patients within the next five years.  In addition, we are implementing a staged development path for our triglyceride-lowering drug, ISIS-APOCIIIRx, that could bring this important new medicine to the market sooner for patients with extremely high and poorly controlled triglycerides who, as a result, are at severe risk of disease," continued Ms. Parshall.

"In addition to the potential near-term product opportunities in our pipeline, we have several drugs that could represent significant licensing opportunities in the next year or two.  With robust Phase 2 data packages, we may be able to command lucrative licensing terms for these drugs.  Among these near-term licensing opportunities is our anticoagulant drug targeting Factor XI and our CRP drug from our cardiovascular franchise.  Both of these drugs have the potential to treat numerous diseases with significant market potential.  In addition, we have several drugs from our metabolic franchise that could complete Phase 2 studies in the next two years and could also provide significant licensing opportunities.  These drugs represent novel approaches to the treatment of type 2 diabetes
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
3. Halozyme Reports First Quarter 2012 Financial Results
4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. IRIDEX Reports 2012 First Quarter Results
7. Cambrex Reports First Quarter 2012 Results
8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
11. Neuland Labs Reports Financial Results For Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals ... VRX) today announced that the company,s Bridgewater, ... from the U.S. Food and Drug Administration (FDA) relating ... records with regards to Sculptra Aesthetic injectable, which was ... Letter pertains to the management of Valeant,s contract manufacturers (rather ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Inc. (OTCQX: DATA), a technology and services company ... trials industry, today announced its participation in the ... will address significant milestones made throughout the pharmaceutical ... technologies are delivering. The EuroMeeting will be held ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... launch of its new formulation of Acetadote ® ... treat acetaminophen poisoning. The proprietary new formulation, which does ... other stabilization or chelating agents, is now stocked at ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2New Acetadote® Formulation Now Available in the U.S. 2New Acetadote® Formulation Now Available in the U.S. 3New Acetadote® Formulation Now Available in the U.S. 4
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... Dotinga HealthDay Reporter TUESDAY, ... women tend to put the brakes on motherhood. And for ... a permanent choice, new research suggests. Women in their ... a child during tough economic times. But, according to the ... childless into their 40s and beyond. The findings suggest ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... is no stranger to the children of Tanzania. What ... to clinical services, including reliable diagnosis and evidence-based treatments. ... for use in Swahili, a major language of the ... Brown University and the University of Georgia (UGA) describe ... two sites in the country and found to be ...
(Date:9/30/2014)... A new study of 58 women conducted by ... on metabolism after eating a high-fat meal equivalent to a ... restaurant, about 930 calories and 60 grams of fat. Researchers ... for 7 hours, conducting the study twice on each woman. ... stressful event in their lives during the previous 24 hours ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3
... the US Consumer Product Safety Commission announced the recalling of ... Feeding Spoons. , The company BabySwede LLC of Sweden ... response to consumer feedback regarding the safety of these spoons ... the spoon were observed to soften and break off. ...
... slapped a fine of Rs.110,000 on a private hospital and ... ,The Balasore district consumer redressal forum Saturday fined the ... operating on the uterus of Shila Jana on July 23, ... ,Jana, a 35-year-old resident of Gobara village under the Ramnagar ...
... reason for pregnant and nursing women to eat a nutritious ... and cabbage// – it could help protect their children from ... ,A new study by scientists from the Linus Pauling ... that supplements of a key phytochemical found in certain vegetables ...
... collaboration with the Indian Medical Association (IMA) to exchange scientific ... train in Britain. ,BMA president Praveen J. Kumar, who ... the IMA, said: "I had a fruitful discussion with the ... a close and active collaboration with the BMA." ...
... his liver to his mother-in-law in November 2003,// he wanted ... wife’s mother and his children’s grandmother. ,But the ... Center on the Donate Life Rose Parade? Float this coming ... and I think it’s important because word needs to get ...
... in Baltimore have warned that many children //are coming down ... specialist Dr. Alicia Neu, co-director of the kidney stone clinic ... kidney stones are coming to us. While this is somewhat ... other conditions are on the rise in children due to ...
Cached Medicine News:Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 2Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 3Health News:Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade 2Health News:Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade 3
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... of the system is the Nightingale Master Patient ... central monitoring station for the Nightingale Monitoring System. ... Nightingale PPM bedside patient monitors, allowing a clinician ... at once., ,The MPC is a Windows ...
... Signs Monitor 300 Series enhances your productivity ... and after procedures. This easy to use ... readings fast and convenient., ,The Vital ... noninvasive blood pressure monitor with the flexibility ...
... The Welch Allyn Atlas monitor is ... conscious sedation, IV anesthesia procedures, and surgery. ... LED numerics that are visible from across ... to learn how to operate the monitor ...
Medicine Products: